DK1221950T3 - Synergitisk kombination af en NK1-receptorantagonist og en GABA-strukturanalog - Google Patents

Synergitisk kombination af en NK1-receptorantagonist og en GABA-strukturanalog

Info

Publication number
DK1221950T3
DK1221950T3 DK00966138T DK00966138T DK1221950T3 DK 1221950 T3 DK1221950 T3 DK 1221950T3 DK 00966138 T DK00966138 T DK 00966138T DK 00966138 T DK00966138 T DK 00966138T DK 1221950 T3 DK1221950 T3 DK 1221950T3
Authority
DK
Denmark
Prior art keywords
receptor antagonist
synergistic combination
structural analog
gaba
gaba structural
Prior art date
Application number
DK00966138T
Other languages
English (en)
Inventor
John Hughes
Lakhbir Singh
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of DK1221950T3 publication Critical patent/DK1221950T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK00966138T 1999-10-07 2000-10-05 Synergitisk kombination af en NK1-receptorantagonist og en GABA-strukturanalog DK1221950T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07

Publications (1)

Publication Number Publication Date
DK1221950T3 true DK1221950T3 (da) 2004-09-20

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00966138T DK1221950T3 (da) 1999-10-07 2000-10-05 Synergitisk kombination af en NK1-receptorantagonist og en GABA-strukturanalog

Country Status (38)

Country Link
EP (2) EP1221950B1 (da)
JP (2) JP2003510356A (da)
KR (1) KR20020060192A (da)
CN (1) CN1387434A (da)
AP (1) AP2002002501A0 (da)
AR (1) AR029646A1 (da)
AT (1) ATE269072T1 (da)
AU (2) AU7663300A (da)
BG (1) BG106548A (da)
BR (1) BR0014598A (da)
CA (1) CA2385930A1 (da)
CO (1) CO5280195A1 (da)
CR (1) CR6614A (da)
CZ (1) CZ20021116A3 (da)
DE (1) DE60011650T2 (da)
DK (1) DK1221950T3 (da)
EA (1) EA004266B1 (da)
EE (1) EE200200185A (da)
ES (1) ES2220542T3 (da)
GT (1) GT200000166A (da)
HR (1) HRP20020286A2 (da)
HU (1) HUP0203466A3 (da)
IL (1) IL148965A0 (da)
IS (1) IS6318A (da)
MA (1) MA26826A1 (da)
MX (1) MXPA02003484A (da)
NO (1) NO20021625D0 (da)
NZ (1) NZ517949A (da)
OA (1) OA12063A (da)
PA (1) PA8504301A1 (da)
PE (1) PE20010708A1 (da)
PL (1) PL357498A1 (da)
PT (1) PT1221950E (da)
SK (1) SK4542002A3 (da)
TR (1) TR200200913T2 (da)
UY (1) UY26376A1 (da)
WO (2) WO2001024792A1 (da)
ZA (1) ZA200202675B (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1094757C (zh) 1996-07-24 2002-11-27 沃尼尔·朗伯公司 用于治疗疼痛的异丁基γ-氨基丁酸及其衍生物
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
EP1499309A4 (en) * 2002-04-24 2008-05-28 Cypress Bioscience Inc PREVENTION AND TREATMENT OF FUNCTIONAL SOMATIC DISEASES, INCLUDING STRESS-BASED DISEASES
US20060039968A1 (en) * 2002-10-08 2006-02-23 Ramalingam Manikandan Gabapentin tablets and method for their preparation
EP1721607A1 (en) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
WO2004084880A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING PAIN USING SMOOTH MUSCLE MODULATORS AND α2δ SUBUNIT CALCIUM CHANNEL MODULATORS
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
KR101786818B1 (ko) 2010-07-30 2017-10-18 도레이 카부시키가이샤 신경장애성 동통의 치료제 또는 예방제
US9089531B2 (en) * 2010-09-28 2015-07-28 The Regents Of The University Of California GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
JP2001502311A (ja) * 1996-10-07 2001-02-20 メルク シヤープ エンド ドーム リミテツド 抗鬱及び/又は抗不安薬としてのcns浸透性nk―1受容体拮抗薬
AU729708B2 (en) * 1996-12-02 2001-02-08 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating severe anxiety disorders

Also Published As

Publication number Publication date
SK4542002A3 (en) 2003-09-11
HRP20020286A2 (en) 2003-08-31
GT200000166A (es) 2002-03-30
MA26826A1 (fr) 2004-12-20
MXPA02003484A (es) 2004-09-10
EP1233766A1 (en) 2002-08-28
EP1221950B1 (en) 2004-06-16
CA2385930A1 (en) 2001-04-12
AU1696201A (en) 2001-05-10
BG106548A (en) 2002-12-29
HUP0203466A2 (hu) 2003-02-28
ZA200202675B (en) 2003-04-15
NO20021625L (no) 2002-04-05
IL148965A0 (en) 2002-11-10
NZ517949A (en) 2003-08-29
AU7663300A (en) 2001-05-10
IS6318A (is) 2002-03-21
PA8504301A1 (es) 2002-08-26
DE60011650T2 (de) 2005-07-14
JP2003510356A (ja) 2003-03-18
AR029646A1 (es) 2003-07-10
BR0014598A (pt) 2002-06-11
OA12063A (en) 2006-05-03
JP2003510355A (ja) 2003-03-18
CZ20021116A3 (cs) 2003-05-14
PT1221950E (pt) 2004-08-31
ES2220542T3 (es) 2004-12-16
AP2002002501A0 (en) 2002-06-30
WO2001024791A1 (en) 2001-04-12
EA200200303A1 (ru) 2002-08-29
EA004266B1 (ru) 2004-02-26
UY26376A1 (es) 2000-12-29
EP1221950A1 (en) 2002-07-17
PE20010708A1 (es) 2001-07-27
PL357498A1 (en) 2004-07-26
DE60011650D1 (de) 2004-07-22
CR6614A (es) 2003-12-04
CO5280195A1 (es) 2003-05-30
HUP0203466A3 (en) 2005-03-29
WO2001024792A1 (en) 2001-04-12
NO20021625D0 (no) 2002-04-05
KR20020060192A (ko) 2002-07-16
TR200200913T2 (tr) 2002-09-23
ATE269072T1 (de) 2004-07-15
CN1387434A (zh) 2002-12-25
EE200200185A (et) 2003-04-15
WO2001024792A9 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
NO20000847D0 (no) Elastiske brønnsementsammensetninger og fremgangsmåter
DK1221950T3 (da) Synergitisk kombination af en NK1-receptorantagonist og en GABA-strukturanalog
AU7061901A (en) N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
NO20012411D0 (no) Pyrrolidin-derivater-CCR-3-reseptorantagonister
DE19956668B4 (de) Duscheinrichtung
NO20022645L (no) Farmasöytisk superdisintegrerende stoff
DK1121116T3 (da) Farmaceutisk præparat af fluvastatin med opretholdt frigivelse
IS2841B (is) Samstæða hluta og lyfjasamsetningar
NO990786D0 (no) Acylaminoalkenylen-amidderivater som NK1 og NK2 antagonister
DK1007024T3 (da) Doseringsformer af sertralin med forsinket frigivelse
NO20031997L (no) CRF-reseptor-antagonist og metoder relatert dertil
DE50006862D1 (de) Gerüsttragvorrichtung
DK1173172T3 (da) Synergistiske virkninger af amlodipin og den hydroxylerede metabolit af atorvastatin
DE29904154U1 (de) Verbesserter Aufbau eines Metronoms
FR2798712B1 (fr) Volant moteur modulaire
GB2347964B (en) Fixing units of a foothold
DK1313500T3 (da) Associationer af dalfopristin/quinupristin med cefpirom
DE50010255D1 (de) Dübel
DK199900093U3 (da) Hurtigtvirkende kunstig muskel
DK1131291T3 (da) 4-aroyl-piperidin-CCR-3-receptorantagonister III
DE59907189D1 (de) Handgelenkprothese
PT1234156E (pt) Dispositivo de fogo de artificio
IT1291652B1 (it) Composizioni farmaceutiche a copertura terapeutica programmata
BR9703682A (pt) Alvenaria modular termo-acústica
ITMI20000129V0 (it) Struttura di ancoraggio per protesi odontoiatriche su impianti endo-ossei